Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Operating Expenses (2020 - 2025)

Historic Operating Expenses for Fulcrum Therapeutics (FULC) over the last 6 years, with Q3 2025 value amounting to $21.9 million.

  • Fulcrum Therapeutics' Operating Expenses fell 1300.64% to $21.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.1 million, marking a year-over-year decrease of 4511.68%. This contributed to the annual value of $101.9 million for FY2024, which is 1019.84% down from last year.
  • Fulcrum Therapeutics' Operating Expenses amounted to $21.9 million in Q3 2025, which was down 1300.64% from $19.8 million recorded in Q2 2025.
  • In the past 5 years, Fulcrum Therapeutics' Operating Expenses registered a high of $36.1 million during Q2 2022, and its lowest value of $19.4 million during Q4 2024.
  • Over the past 5 years, Fulcrum Therapeutics' median Operating Expenses value was $27.8 million (recorded in 2023), while the average stood at $26.5 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first surged by 5009.35% in 2022, then crashed by 3268.54% in 2024.
  • Quarter analysis of 5 years shows Fulcrum Therapeutics' Operating Expenses stood at $28.6 million in 2021, then rose by 0.14% to $28.7 million in 2022, then increased by 0.72% to $28.9 million in 2023, then plummeted by 32.69% to $19.4 million in 2024, then grew by 12.5% to $21.9 million in 2025.
  • Its last three reported values are $21.9 million in Q3 2025, $19.8 million for Q2 2025, and $19.4 million during Q4 2024.